PT  - JOURNAL ARTICLE
AU  - Azargoonjahromi, Ali
AU  - Ashrafi, Mitra
AU  - Abroushan, Donya
AU  - Ramezannezhad, Elham
AU  - Sadeghi, Mohammad
AU  - Pooresmaeil Niaki, Seyede Roxane
AU  - Radmanesh, Mehrsa
AU  - Haratian, Amin
AU  - Taki, Azin
AU  - Nekahi, Negar
AU  - Moshiri, Yeganeh
AU  - Rahimi, Marzieh
AU  - Fadavian, Heidar
AU  - Mousavi, Seyede Maryam
AU  - Fard, Atousa Moghadam
AU  - Mayeli, Mahsa
TI  - High-Density Lipoprotein (HDL) Subtypes Adversely Alter Brain Structure in Mild Cognitive Impairment: A Tensor-Based Morphometry Analysis
AID  - 10.1101/2024.08.20.24312114
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.08.20.24312114
4099  - http://medrxiv.org/content/early/2024/08/21/2024.08.20.24312114.short
4100  - http://medrxiv.org/content/early/2024/08/21/2024.08.20.24312114.full
AB  - High-density lipoprotein (HDL) cholesterol is typically protective for cognitive function due to its anti-inflammatory, antioxidant, and vascular health benefits. However, recent studies indicated that certain HDL subtypes might be associated with adverse brain structural changes, commonly seen in mild cognitive impairment (MCI). Thus, further research is needed to understand the intricate relationship between HDL levels and brain structure, potentially leading to more effective therapeutic strategies. The current study aimed to investigate the impact of HDL subtypes, such as XL_HDL_P, M_HDL_FC_PCT, M_HDL_P, M_HDL_C, and M_HDL_CE, as well as APOA1, on brain structure in individuals with MCI using tensor-based morphometry (TBM). The study analyzed ADNI data from subjects with at least two serial MRI scans, processed using the Mayo TBM-Symmetric Normalization (SyN) pipeline and SyN for longitudinal measures. The CDR and ADAS scores were used to assess the severity of cognitive impairment and disease progression in our study participants. Significant ROIs were identified from a Mayo Clinic training set, and TBM-SyN scores were computed. The significant correlation was considered with p-values less than 0.05. The study found significant negative effects of several lipoproteins on TBM scores in individuals with MCI. Specifically, XL_HDL_P, with an effect size of - 0.00145 (p=0.029), and M_HDL_FC_PCT, with an effect size of -0.00199 (p=0.0016), were linked to lower TBM scores. Similarly, M_HDL_P (−0.00138, p=0.028), M_HDL_C (−0.00140, p=0.025), M_HDL_CE (−0.00136, p=0.031), and APOA1 (−0.00149, p=0.017) also showed significant associations. These findings indicate that higher levels of HDL subtype cholesterol are significantly associated with reduced TBM scores, suggesting that elevated levels are linked to adverse structural brain changes, such as atrophy, in individuals with MCI, potentially contributing to cognitive decline.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used available human data that were originally located at the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (https://adni.loni.usc.edu/).The ADNI study is ethically approved and operated in accordance with the Declaration of Helsinki, 1964.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data used in this research was obtained from Alzheimer's Disease Neuroimaging Initiative (ADNI) and is available with permission to all researchers.HDLHigh-density lipoproteinBBBblood-brain barrierMCImild cognitive impairmentADAlzheimer’s diseaseAβamyloid-betaTBMTensor-based morphometryADAS-CogAlzheimer’s Disease Assessment Scale-Cognitive SubscaleCDRClinical Dementia RatingCSFcerebrospinal fluidDBCdifferential bias correction